全文获取类型
收费全文 | 125篇 |
免费 | 13篇 |
专业分类
儿科学 | 3篇 |
妇产科学 | 3篇 |
基础医学 | 15篇 |
临床医学 | 26篇 |
内科学 | 38篇 |
神经病学 | 4篇 |
特种医学 | 1篇 |
外科学 | 11篇 |
预防医学 | 12篇 |
药学 | 16篇 |
肿瘤学 | 9篇 |
出版年
2023年 | 1篇 |
2022年 | 10篇 |
2021年 | 4篇 |
2020年 | 5篇 |
2019年 | 9篇 |
2018年 | 6篇 |
2017年 | 3篇 |
2016年 | 5篇 |
2015年 | 3篇 |
2014年 | 7篇 |
2013年 | 5篇 |
2012年 | 16篇 |
2011年 | 17篇 |
2010年 | 6篇 |
2009年 | 6篇 |
2008年 | 7篇 |
2007年 | 5篇 |
2006年 | 7篇 |
2005年 | 7篇 |
2004年 | 4篇 |
2002年 | 2篇 |
2001年 | 1篇 |
1995年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有138条查询结果,搜索用时 15 毫秒
61.
Rebecca Rogers Gloria Bachmann Zhanna Jumadilova Franklin Sun Jon D. Morrow Zhonghong Guan Tamara Bavendam 《International urogynecology journal》2008,19(11):1551-1557
We evaluated overactive bladder (OAB) symptoms and sexual and emotional health in sexually active women with OAB/urgency urinary
incontinence (UUI) treated with tolterodine extended release (ER). Sexually active women with OAB symptoms were randomized
to placebo or tolterodine ER. Five-day bladder diaries, Sexual Quality of Life Questionnaire—Female (SQOL-F), Pelvic Organ
Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ), and Hospital Anxiety and Depression Scale (HAD) were completed
at baseline and week 12. Tolterodine ER (n = 201; mean ± SD age, 49 ± 12 years) reduced UUI episodes (P = 0.0029), total (P = 0.0006) and OAB (P < 0.0001) micturitions, and pad use per 24 h (P = 0.0024), and was associated with improvements in SQOL-F (P = 0.004), PISQ total (P = 0.009), and HAD Anxiety (P = 0.03) scores versus placebo (n = 210; mean ± SD age, 47 ± 12 years). OAB symptoms improved with tolterodine ER as did the scores of sexual health and anxiety
measures in sexually active women with OAB. 相似文献
62.
63.
64.
Getz K Hallinan Z Simmons D Brickman MJ Jumadilova Z Pauer L Wilenzick M Morrison B 《Expert review of clinical pharmacology》2012,5(2):149-156
Although the overwhelming majority of study volunteers want to receive information on the results of their participation in clinical trials, research suggests that most study volunteers never do. CISCRP - an independent nonprofit organization - in collaboration with Pfizer, conducted a study evaluating the feasibility and impact of a new process to inform study volunteers of the results of their clinical trials. Two process components were evaluated via surveys, focus groups, and interviews with volunteers and investigative site staff: a series of ongoing post-trial communications to set expectations for when trial results would be received; and routine development and delivery of the lay language trial results summary. The results of this assessment show that study volunteers and investigative site staff are extremely receptive to receiving clinical trial results and that the process of preparing and disseminating clinical trial results is feasible and generally easy to execute. The results also indicate that study volunteer comprehension of basic facts about their clinical trial pre- and post-test increased by as much as 65.6 percentage points, and suggest that this communication initiative may positively impact volunteer recruitment, retention and long-term trust in the clinical research enterprise. 相似文献
65.
Esnault VL Brown EA Apetrei E Bagon J Calvo C DeChatel R Holdaas H Krcmery S Kobalava Z;Amlodipine Versus Enalapril in Renal failure 《Clinical therapeutics》2008,30(3):482-498
BACKGROUND: Placebo-controlled trials have found that angiotensin-converting enzyme inhibitors (ACEIs) decrease proteinuria and slow the progression of nondiabetic nephropathies. However, head-to-head comparisons of ACEIs and calcium channel blockers (CCBs) have shown conflicting results. Indeed, a recent metaanalysis concluded that there is still uncertainty about the greater renoprotection seen with ACEIs or angiotensin II receptor blockers in nondiabetic patients with renal disease, particularly when using true glomerular filtration rate (GFR) as the primary outcome. OBJECTIVE: The objective of this 3-year, randomized, multicenter, double-blind, placebo-controlled study was to compare true GFR decline (measured by yearly 51Cr-EDTA blood clearance) in nondiabetic, nonnephrotic adult hypertensive patients with estimated creatinine clearance of 20 to 60 mL/min.1.73 m(2), when randomized to a CCB (amlodipine, 5-10 mg/d) or an ACEI (enalapril, 5-20 mg/d). METHODS: Patients (aged 18-80 years) entered a 4-week placebo run-in washout period and previous antihypertensive drugs were tapered off over 2 weeks. Add-on treatments were atenolol (50-100 mg/d), loop diuretics (furosemide, 20-500 mg/d or torsemide, 5-200 mg/d), alpha-blockers (prazosin, 2.5-5 mg/d or doxazosin, 1-16 mg/d), and centrally acting drugs (rilmenidine, 1-2 mg/d or methyldopa, 250-500 mg/d). The primary end point was true GFR measured by yearly (51)Cr-EDTA blood clearance. Secondary end points included a clinical composite of renal events and tolerability collected by a full clinical and laboratory evaluation at each study visit. Post hoc analyses for the change in GFR, proteinuria, and time to clinical events were also planned on baseline proteinuria subgroups (<1 and >or=1 g/d) before unblinding the database. RESULTS: Three hundred eighteen patients entered the run-in period and 263 patients (156 men/107 women; mean age, 58 years) were randomized to receive either amlodipine (5 mg/d, n=132) or enalapril (5 mg/d, n=131). Blood pressure declined from 165/102 mm Hg to 138/84 mm Hg and 138/85 mm Hg with amlodipine and enalapril, respectively (no between-group significance). Only 20.8% of the patients randomized to ACEI treatment received diuretics at the last observation. No statistically significant difference was found between amlodipine and enalapril in GFR decline (-4.92 and -3.98 mL/min.1.73 m(2), respectively, at last observation) and composite secondary end point after a median follow-up of 2.9 years, including in the subgroup of patients with proteinuria >1 g/d at baseline. Protein excretion rate decreased significantly from baseline in patients taking enalapril plus diuretics (median -270 mg/d; P<0.001) but not in patients taking amlodipine plus diuretics (-25 mg/d at last observation). CONCLUSION: In this cohort of nondiabetic, nonnephrotic hypertensive patients, no statistically significant difference in true GFR decline was found over 3 years between amlodipine-treated patients and enalapril-treated patients with main add-on treatment with ss-blockers, including in the subgroup of patients with proteinuria >1 g/d. 相似文献
66.
Behavioural and brain left-right asymmetries are a common feature among the animal kingdom. Lateralization often manifests itself at the population-level with most individuals showing the same direction of lateral bias. Theoretical model based on evolutionary stable strategy predicts that lateralization at the population-level is more likely to characterize social rather than solitary species. Empirical data supporting this hypothesis has been recently obtained in Hymenoptera showing that eusocial honeybees present an asymmetrical use of the antennae: the right antenna is involved in olfactory learning and present more olfactory receptors. However, no evidences about the role of antennal asymmetries in social interactions have been provided so far. Highly social ant species belonging to Formica rufa group are a good model for investigating natural communication because they are able to pass exact information to their nest mates. We applied the "binary tree" experimental paradigm, which allowed us to observe different types of antennal contacts performed by ants out of their nest. To examine possible asymmetrical use of the right and left antenna, we focused on "feeding" (the simplest) contacts where a "donor" ant is exchanging food with a "receiver" ant through trophallaxis. We observed a population-level asymmetry, with the "receiver" ant using the right antenna significantly more often than the left antenna. This study provides the first evidence of lateralization in antennal contacts in ants, and seems to support the hypothesis of mathematical models on the evolution of lateralization suggesting that the alignment of lateralization at the population-level matters in social interactions. 相似文献
67.
Zhanna Kobalava Svetlana Villevalde Yulia Kotovskaya Holger Hinrichsen Marc Petersen-Sylla Andreas Zaehringer Yinuo Pang Iris Rajman Jasna Canadi Marion Dahlke Peter Lloyd Atef Halabi 《British journal of clinical pharmacology》2015,79(6):937-945
Aims
Serelaxin is a recombinant form of human relaxin-2 in development for treatment of acute heart failure. This study aimed to evaluate the pharmacokinetics (PK) of serelaxin in patients with hepatic impairment. Secondary objectives included evaluation of immunogenicity, safety and tolerability of serelaxin.Methods
This was an open-label, parallel group study () comparing the PK of serelaxin following a single 24 h intravenous (i.v.) infusion (30 μg kg−1 day−1) between patients with mild, moderate or severe hepatic impairment (Child–Pugh class A, B, C) and healthy matched controls. Blood sampling and standard safety assessments were conducted. Primary non-compartmental PK parameters [including area under the serum concentration–time curve AUC(0–48 h) and AUC(0–∞) and serum concentration at 24 h post-dose (C24h)] were compared between each hepatic impairment group and healthy controls. NCT01433458Results
A total of 49 subjects (including 25 patients with hepatic impairment) were enrolled, of which 48 subjects completed the study. In all groups, the serum concentration of serelaxin increased over the first few hours of infusion, reached steady-state at 12–24 h and then declined following completion of infusion, with a mean terminal half-life of 7–8 h. All PK parameter estimates were comparable between each group of patients with hepatic impairment and healthy controls. No serious adverse events, discontinuations due to adverse events or deaths were reported. No serelaxin treatment-related antibodies developed during this study.Conclusions
The PK and safety profile of serelaxin were not affected by hepatic impairment. No dose adjustment is needed for serelaxin treatment of 48 h i.v. infusion in patients with hepatic impairment. 相似文献68.
69.
Lipatova Z Belogortseva N Zhang XQ Kim J Taussig D Segev N 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(18):6981-6986
The key regulators of intracellular trafficking, Ypt/Rab GTPases, are stimulated by specific upstream activators and, when activated, recruit specific downstream effectors to mediate membrane-transport events. The yeast Ypt1 and its human functional homolog hRab1 regulate both endoplasmic reticulum (ER)-to-Golgi transport and autophagy. However, it is not clear whether the mechanism by which these GTPases regulate autophagy depends on their well-documented function in ER-to-Golgi transport. Here, we identify Atg11, the preautophagosomal structure (PAS) organizer, as a downstream effector of Ypt1 and show that the Ypt1-Atg11 interaction is required for PAS assembly under normal growth conditions. Moreover, we show that Ypt1 and Atg11 colocalize with Trs85, a Ypt1 activator subunit, and together they regulate selective autophagy. Finally, we show that Ypt1 and Trs85 interact on Atg9-containing membranes, which serve as a source for the membrane component of the PAS. Together our results define a Ypt/Rab module--comprising an activator, GTPase, and effector--that orchestrates the onset of selective autophagy, a process vital for cell homeostasis. Furthermore, because Atg11 does not play a role in ER-to-Golgi transport, we demonstrate here that Ypt/Rabs can regulate two independent membrane-transport processes by recruiting process-specific effectors. 相似文献
70.
Stephen Antonysamy Zahid Bonday Robert M. Campbell Brandon Doyle Zhanna Druzina Tarun Gheyi Bomie Han Louis N. Jungheim Yuewei Qian Charles Rauch Marijane Russell J. Michael Sauder Stephen R. Wasserman Kenneth Weichert Francis S. Willard Aiping Zhang Spencer Emtage 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(44):17960-17965
Protein arginine methyltransferases (PRMTs) play important roles in several cellular processes, including signaling, gene regulation, and transport of proteins and nucleic acids, to impact growth, differentiation, proliferation, and development. PRMT5 symmetrically di-methylates the two-terminal ω-guanidino nitrogens of arginine residues on substrate proteins. PRMT5 acts as part of a multimeric complex in concert with a variety of partner proteins that regulate its function and specificity. A core component of these complexes is the WD40 protein MEP50/WDR77/p44, which mediates interactions with binding partners and substrates. We have determined the crystal structure of human PRMT5 in complex with MEP50 (methylosome protein 50), bound to an S-adenosylmethionine analog and a peptide substrate derived from histone H4. The structure of the surprising hetero-octameric complex reveals the close interaction between the seven-bladed β-propeller MEP50 and the N-terminal domain of PRMT5, and delineates the structural elements of substrate recognition. 相似文献